Gutierrez Linda S
Wilkes University, Wilkes-Barre, Pennsylvania U.S.A.
Biomark Insights. 2008;3:171-8. doi: 10.4137/bmi.s630.
Crohn's disease and ulcerative colitis are inflammatory bowel diseases (IBD) quite common in the United States and other Western countries. Patients suffering IBD are at greater risk of developing colorectal adenocarcinoma than the general population. Both, the adenoma-carcinoma and the inflammation-carcinogenesis processes are characterized by active angiogenesis. Recent studies also have shown that anti-angiogenesis might be a novel therapeutic approach for IBD. Thrombospondin 1 (TSP1) is an extracellular protein well known for its anti-angiogenic properties. TSP1 also has key functions in inflammation, which is assumed to be the primary cause for carcinogenesis in IBD. This review is focused on the role of TSP1 in colorectal carcinogenesis. The therapeutic effects of TSP derived-peptides on inhibiting the inflammationcarcinogenesis progression are also discussed.
克罗恩病和溃疡性结肠炎是在美国和其他西方国家相当常见的炎症性肠病(IBD)。患有IBD的患者比普通人群患结直肠癌的风险更高。腺瘤-癌和炎症-致癌过程均以活跃的血管生成特征。最近的研究还表明,抗血管生成可能是IBD的一种新型治疗方法。血小板反应蛋白1(TSP1)是一种细胞外蛋白,以其抗血管生成特性而闻名。TSP1在炎症中也具有关键作用,炎症被认为是IBD致癌的主要原因。本综述重点关注TSP1在结直肠癌发生中的作用。还讨论了TSP衍生肽对抑制炎症致癌进展的治疗效果。